linjc16/ctgov huggingface dataset:
Predictive Value of pCLE Findings in Pediatric IBD

Study Overview
=================
Brief Summary
-----------------
Studies over the past two decades have convincingly demonstrated the role of barrier dysfunction in the pathogenesis of inflammatory bowel disease. It previously shown that optical biopsy with probe-based confocal laser endomicroscopy (pCLE) could be used to assess mucosal barrier function. Furthermore, mucosal barrier dysfunction on pCLE was shown to be predictive of disease relapse in adult IBD patients. The purpose of the current study is to determine the predictive value of pCLE findings in pediatric IBD patients.

Official Title
-----------------
Predictive Value of pCLE Findings in Pediatric IBD

Conditions
-----------------
Inflammatory Bowel Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: signed informed consent patients with established IBD Exclusion Criteria: Any kind of allergy Bronchial asthma Liver or kidney disease Inability to sign informed consent

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 21 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary study end-point was moderate to severe flare requiring hospitalization after pCLE | The purpose of the current study is to determine the predictive value of pCLE findings in pediatric IBD patients. | follow up period was a median of 18 months (range 4 to 33) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IBD, Pediatrics, pCLE
Cytokine Profile of the Uterine Secretome After Therapeutic Endometrial Scratching

Study Overview
=================
Brief Summary
-----------------
This study investigates the impact of endometrial scratching on endometrial secretion, when correlated to pregnancy.

Official Title
-----------------
Cytokine Profile of the Uterine Secretome After Therapeutic Endometrial Scratching

Conditions
-----------------
Infertility, Female

Intervention / Treatment
-----------------
* Other: Pipelle de Cornier


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: IVF or ICSI patients with ≥1 previous implantation failure, despite transfer of a top quality embryo or blastocyst. Antagonist treatment FSH: 2-12 IU/L BMI: 18-32 Regular menstrual cycle Written consent Exclusion Criteria: Suspected intrauterine abnormalities Planned use of specialized media or AHA

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Randomized clinical trial
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: No intervention<br>Standard treatment | |
| Experimental: Intervention<br>Endometrial scratching before standard treatment | Other: Pipelle de Cornier<br>* RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cytokine profile of the uterine secretome after therapeutic endometrial scratching | The secretome is analyzed using a Multiplex analysis with 45 cytokines, chemokines and growth factors from ProcartaPlex Immunoassay Kit, Affymetrix, eBioscience. The samples are normalized for total protein content using a Nanodrop spectrophometer, and the protein composition is further determined by sodium dodecyl sulphate-polyacrylamide gel electropheresis (SDS-PAGE). | Within 12 months | 
| Immunoassay Kit: | BDNF, EGF, Eotaxin, FGF-2, GMCSF, GRO-alpha, HGF, IFN alpha, IFN gamma, IL-1RA, IL-1alpha, IL-1 beta, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL17-A, IL-18, IL-21, IL-22, IL-23, IL-27, IL-31, IP-10, LIF, MCP-1, MIP-1 alpha, MIP-1 beta, NGF beta, RANTES, PDGF-BB, PÅIGF-1, SCF, SDF-1 alpha, TNF alpha, TNF beta, VEGF-A, VEGF-D | Within 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Endometrium, Cytokines, Endometrial secretion, Implantation, Endometrial scratching
Efficacy Trial of Gemcitabine Containing Regimens As Preoperative Chemotherapy in Non Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
To evaluate the rate of complete pathological response after 3 cycles of gemcitabine containing chemotherapy.

Official Title
-----------------
Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (Gemcitabine/Carboplatin and Gemcitabine/Paclitaxel) When Used as Preoperative Chemotherapy In Patients With Stage I and II NSCLC

Conditions
-----------------
Carcinoma, Non Small Cell Lung

Intervention / Treatment
-----------------
* Drug: Gemcitabine
* Drug: Carboplatin
* Drug: Paclitaxel


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Histologically or cytologically confirmed non small cell lung cancer No prior chemotherapy or radiation for non small cell lung cancer No prior malignancy Exclusion Criteria: Pregnancy or breastfeeding Serious concomitant disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gemcitabine|nan|
|Drug: Carboplatin|nan|
|Drug: Paclitaxel|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pathological complete response rate, in previously untreated patients with clinical Stage I and II non-small cell lung cancer (NSCLC). |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate, disease free survival,toxicities including pulmonary toxicity, operative mortality, and quality of life. |  |  |
Diagnosis and Follow-up of Patients With Subclinical Hypothyroidism

Study Overview
=================
Brief Summary
-----------------
Long term follow-up of the patients with delayed TSH elevation or subclinical hypothyroidism has been seldom reported. The purpose of this study was to explore the diagnostic criteria for subclinical hypothyroidism and the initial dosage of L-thyroxine through long-term follow up for infants with subclinical hypothyroidism ，and evaluate the curative effect.

Detailed Description
-----------------
Long term follow-up of the patients with delayed TSH elevation or subclinical hypothyroidism has been seldom reported. The purpose of this study was to explore the diagnostic criteria for subclinical hypothyroidism and the initial dosage of L-thyroxine through long-term follow up for infants with hyperthyrotropinemia，and evaluate the curative effect.All live-born neonates in province took part in the screening program from October, 1999 to September ,2006. Laboratory tests are performed as a time resolved fluoro-immunoassay (TRFIA). TSH is measured with a cut-off > 9 mU/L. The diagnostic standard for subclinical hypothyroidism was: TSH ≥ 20 mU/L, T3 and T4 normal or low-normal ,or TSH > 5.6 mU/L and < 20 mU/L on initial determination and on follow-up or TSH levels increase on follow-up and/or gradually declining T4 levels.L-Thyroxine was administered for substitution therapy. After 2 years therapy，allround evaluation was performed. Compare the correlation to effects with different level of TSH、starting time of therapy and environment. Compare the effects between subclinical、temporary and permanent hypothyroidism.

Conditions
-----------------
Congenital Hypothyroidism, L-Thyroxine, Follow-Up

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The diagnostic standard for manifest hypothyroidism and subclinical hypothyroidism was defined as follows: Hypothyroidism - TSH > 40 mU/L and T3 and T4 below the reference range or TSH > 40 mU/L, T3 normal and T4 below the reference range [2] Subclinical hypothyroidism - TSH ≥ 20 mU/L, T3 and T4 normal or low-normal or TSH > 5.6 mU/L and < 20 mU/L on initial determination and on follow-up or TSH levels increase on follow-up and/or gradually declining T4 levels.

Ages Eligible for Study
-----------------
Maximum Age: 5 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Congenital Hypothyroidism, diagnosis, L-thyroxine, newborn screening
A Measles, Mumps, and Rubella Investigational Vaccine Trial (V205C-010)(COMPLETED)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to test the safety of a measles, mumps, and rubella study vaccine made from a new measles stock seed (a component of the vaccine made in 2003) with rHA (recombinant human albumin).

Detailed Description
-----------------
The duration of treatment is 6 weeks.

Official Title
-----------------
A Comparison of the Safety, Tolerability, and Immunogenicity of V205C Manufactured From the 2003 Measles Stock Seed With Recombinant Human Albumin (rHA) Versus Currently Licensed V205C Manufactured From the 1967 Measles Stock Seed With Human Serum Albumin (HSA) in Healthy Children 12 to 18 Months of Age

Conditions
-----------------
Measles

Intervention / Treatment
-----------------
* Biological: V205C, measles, mumps, and rubella virus vaccine live
* Biological: Comparator: Measles, Mumps, and Rubella Virus Vaccine Live


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy children 12 to 18 months of age. Exclusion Criteria: Previous receipt of measles, mumps, rubella and/or varicella vaccine. Prior infection or exposure to (within last 4 weeks) measles, mumps, rubella, varicella and/or zoster. Any medical condition that might interfere with the immune response to the given vaccines (including HIV infection and/or cancer) or has undergone immunosuppressive (weakens your body's ability to fight infection) therapy. History of seizures (convulsions) Allergies to any component of the vaccine, including sorbitol, gelatin, or neomycin. A recent (within the last 3 days) illness resulting in a fever (underarm temperature greater than 99.5° F [37.5° C]).

Ages Eligible for Study
-----------------
Minimum Age: 12 Months
Maximum Age: 18 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Biological: V205C, measles, mumps, and rubella virus vaccine live|nan|
|Biological: Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antibody response rate to measles at 6 weeks postvaccination |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Geometric mean titers to measles by ELISA at 6 weeks postvaccination |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Prevention of Measles
Graves' Orbitopathy and Hypercholesterolemia

Study Overview
=================
Brief Summary
-----------------
The investigators have recently observed retrospectively that the occurrence of Graves' Orbitopathy in patients with Graves' disease is less frequent in patients with normal cholesterol levels, in line with another recent observation suggesting that statins play a protective role in Graves' patients from developing Graves' Orbitopathy. The present study is designed in order to investigate the possible association between Graves' Orbitopathy and high cholesterol level as well as the relation between Graves' Orbitopathy degree and high cholesterol level

Official Title
-----------------
A Prospective Study on the Association Between Graves' Orbitopathy and Hypercholesterolemia

Conditions
-----------------
Graves' Ophthalmopathy, Hypercholesterolemia

Intervention / Treatment
-----------------
* Other: No intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Graves' disease with Graves' Orbitopathy Graves' disease without Graves' Orbitopathy Exclusion Criteria: Previous treatment with radioiodine Previous treatment with thyroidectomy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Graves' Disease<br>Patients with Graves' disease, without Graves' Orbitopathy | Other: No intervention<br>* No intervention<br>|
| Graves' Orbitopathy<br>Patients with Graves' disease, with Graves' Orbitopathy | Other: No intervention<br>* No intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between LDL cholesterol levels and Graves' Orbitopathy | Relationship between the levels of LDL cholesterol and the presence of Graves' Orbitopathy | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between LDL cholesterol levels and the activity of Graves' Orbitopathy | Relationship between the levels of LDL cholesterol and the Graves' Orbitopathy clinical activity score | Baseline | 
| Relationship between LDL cholesterol levels and the severity of Graves' Orbitopathy | Relationship between the levels of LDL cholesterol the Graves' Orbitopathy severity score (NOSPECS score) | Baseline |
Radiological Study of PENG Block Depth

Study Overview
=================
Brief Summary
-----------------
This study evaluates the depth of anatomical landmarks required in regional anaesthesia to perform either Femoral Nerve Block or PENG Block. Measures will be performed on abdominal and pelvic computed tomography as part of daily routine patient care.

Detailed Description
-----------------
PENG Block is a new approach in regional anesthesia for hip surgery. The anatomical landmarks used to perform PENG Block are deeper than those for Femoral Nerve Block. Nevertheless, depth required for PENG Block is not yet evaluated since it may vary between patients. Daily routine abdominal and pelvic computed tomography allow such anatomical description.

Official Title
-----------------
Observational Tomodensitometric Study of the Anatomical Landmarks Depth Required to Perform Femoral Nerve Block or PENG Block. The Tomo-PENG Study.

Conditions
-----------------
Regional Anesthesia, Computed Tomography, Anatomical Description

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adult patients who have had a CT scan including visualization of the pelvis and who have expressed no opposition Exclusion Criteria: pregnancy Subject presenting a pathology likely to modify the anatomical landmarks studied: ie pelvic fracture, psoas haematoma, previous pelvic surgery or hip prosthesis or femoral bypass

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PENG Block depth | Measure of puncture depth required to achieve a PENG Block on CT Scann images | 1 hour after radiological examination | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Femoral Nerve Block depth | Measure of puncture depth required to achieve a Femoral Nerve Block on CT Scann images | 1 hour after radiological examination | 
| puncture angle needed | Measure of puncture angle that would be required to achieve a PENG Block depth on CT Scann images | 1 hour after radiological examination | 
| needle length needed | Measure of needle length that would be required to achieve a PENG Block depth on CT Scann images | 1 hour after radiological examination | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PENG block
The Combined Effect of 2,3-Dimercaptosuccinic Acid and Multi-Nutrients on Children in Lead Poisoning

Study Overview
=================
Brief Summary
-----------------
Lead poisoning remains a common disease among children despite successful public health efforts that reduced its prevalence.Our study was designed to test the hypothesis that lead-poisoning children (BLLs:100-440µg/L) who were given DMSA and multi-nutrients would have a greater fall than children of other groups at 12 weeks of follow-up.

Conditions
-----------------
Lead Poisoning

Intervention / Treatment
-----------------
* Drug: 2,3-dimercaptosuccinic acid


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Initial BLLs 100-440µg/L Age 3-6y No more than two main residences House cleaned (no lead contaminated) Normal intake history and physical Exclusion Criteria: Chelation in the past 12 weeks Concomitant Fe deficiency(ferritin<16ng/ml) Hemoglobin<10.5g/dL Medications affecting mineral metabolism

Ages Eligible for Study
-----------------
Minimum Age: 3 Years
Maximum Age: 6 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: 2,3-dimercaptosuccinic acid|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
2,3-dimercaptosuccinic acid, Blood Lead Levels, children, multi-nutrients
A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON)

Study Overview
=================
Brief Summary
-----------------
The study will examine which dose of YM178 is best in terms of efficacy, safety and tolerability compared to placebo and compared to tolterodine, a marketed product.

Official Title
-----------------
A Randomized, Double-blind, Parallel Group, Placebo and Active Controlled, Multicenter Dose Ranging Study With the Beta-3 Agonist YM178 in Patients With Symptomatic Overactive Bladder

Conditions
-----------------
Overactive Bladder

Intervention / Treatment
-----------------
* Drug: YM178


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years suffering from overactive bladder (OAB) for more than 3 months Exclusion Criteria: Pregnant and breastfeeding women Any medical condition or need for co-medication which interferes with the drug under investigation (YM178) or the comparator (tolterodine)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: YM178|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Over Active Bladder, Urinary incontinence, YM178, Symptomatic Over Active Bladder